The healthcare landscape for blood sugar is changing, and transdermal GLP-1 delivery systems represent a potential development. Unlike injections, this approach offers a simpler way to provide GLP-1 therapies. These transdermal systems steadily release the drug through the epidermis offering a stable dose of the therapeutic agent, which can enhance